Zacks Investment Research downgraded shares of Allena Pharmaceuticals (NASDAQ:ALNA) from a hold rating to a sell rating in a research report sent to investors on Tuesday.
According to Zacks, “Allena Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in developing and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders primarily in the United States. The companys product candidate includes ALLN-177 and ALLN-346 which are in clinical stages. Allena Pharmaceuticals, Inc. is headquartered in Newton, Massachusetts. “
A number of other research analysts have also recently issued reports on the stock. Cowen reaffirmed a buy rating on shares of Allena Pharmaceuticals in a report on Wednesday, August 8th. B. Riley raised their price target on shares of Allena Pharmaceuticals from $23.50 to $25.00 and gave the stock a buy rating in a report on Wednesday, August 8th. LADENBURG THALM/SH SH assumed coverage on shares of Allena Pharmaceuticals in a report on Thursday, August 2nd. They issued a buy rating and a $23.00 price target for the company. Finally, Wedbush reaffirmed an outperform rating and issued a $38.00 price target on shares of Allena Pharmaceuticals in a report on Tuesday, July 24th. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company. Allena Pharmaceuticals has a consensus rating of Buy and a consensus price target of $29.14.
Shares of ALNA opened at $10.94 on Tuesday. The company has a market capitalization of $222.88 million and a price-to-earnings ratio of -2.30. Allena Pharmaceuticals has a twelve month low of $6.13 and a twelve month high of $17.56. The company has a debt-to-equity ratio of 0.15, a current ratio of 29.32 and a quick ratio of 29.32.
Allena Pharmaceuticals (NASDAQ:ALNA) last announced its earnings results on Tuesday, August 7th. The company reported ($0.42) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.40) by ($0.02). On average, equities analysts predict that Allena Pharmaceuticals will post -1.76 earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. raised its holdings in shares of Allena Pharmaceuticals by 2.2% in the first quarter. BlackRock Inc. now owns 231,654 shares of the company’s stock worth $2,553,000 after buying an additional 4,879 shares during the last quarter. Wells Fargo & Company MN raised its holdings in shares of Allena Pharmaceuticals by 246.4% in the first quarter. Wells Fargo & Company MN now owns 9,336 shares of the company’s stock worth $103,000 after buying an additional 6,641 shares during the last quarter. Rhumbline Advisers purchased a new position in shares of Allena Pharmaceuticals in the second quarter worth $133,000. Citadel Advisors LLC purchased a new position in shares of Allena Pharmaceuticals in the first quarter worth $124,000. Finally, Spark Investment Management LLC purchased a new position in shares of Allena Pharmaceuticals in the second quarter worth $208,000. 84.90% of the stock is owned by institutional investors and hedge funds.
Allena Pharmaceuticals Company Profile
Allena Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is ALLN-177, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults.
Further Reading: Understanding the different types of bonds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.